Compare SJM & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SJM | ASND |
|---|---|---|
| Founded | 1897 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 12.2B |
| IPO Year | N/A | 2015 |
| Metric | SJM | ASND |
|---|---|---|
| Price | $100.01 | $205.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $116.42 | ★ $256.27 |
| AVG Volume (30 Days) | ★ 1.8M | 640.2K |
| Earning Date | 11-25-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,773,200,000.00 | $758,592,045.00 |
| Revenue This Year | $5.00 | $99.74 |
| Revenue Next Year | $2.20 | $79.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 97.46 |
| 52 Week Low | $93.30 | $118.03 |
| 52 Week High | $121.48 | $223.19 |
| Indicator | SJM | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 49.03 |
| Support Level | $100.00 | $198.30 |
| Resistance Level | $104.44 | $218.50 |
| Average True Range (ATR) | 2.39 | 9.16 |
| MACD | -0.60 | -0.64 |
| Stochastic Oscillator | 8.49 | 28.05 |
J.M. Smucker is a packaged food company that primarily sells through the US retail channel (73% of fiscal 2025 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of sweet baked snacks (through the Hostess acquisition) and international (primarily Canada). Retail coffee is its largest category (32% of sales) with brands Folgers and Dunkin'. Pet foods (19% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 22% comes from frozen handhelds and spreads, through brands Jif, Smucker's, and Uncrustables. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.